Optimization of Cyclic Plasmin Inhibitors: From Benzamidines to Benzylamines.
Hinkes, S., Wuttke, A., Saupe, S.M., Ivanova, T., Wagner, S., Knorlein, A., Heine, A., Klebe, G., Steinmetzer, T.(2016) J Med Chem 59: 6370-6386
- PubMed: 27280436 
- DOI: 10.1021/acs.jmedchem.6b00606
- Primary Citation of Related Structures:  
5EG4 - PubMed Abstract: 
New macrocyclic plasmin inhibitors based on our previously optimized P2-P3 core segment have been developed. In the first series, the P4 residue was modified, whereas the 4-amidinobenzylamide in P1 position was maintained. The originally used P4 benzylsulfonyl residue could be replaced by various sulfonyl- or urethane-like protecting groups ...